Head and Neck-Journal for the Sciences and Specialties of the Head and Neck最新文献

{"title":"Prognosis and Phenotypes of Advanced Head and Neck Carcinoma Associated With Hypercalcemia.","authors":"Elodie Mamou, Paul Gougis, Baptiste Abbar, Jean-Philippe Spano, Laetitia Morardet, Aurore Vozy","doi":"10.1002/hed.28126","DOIUrl":"https://doi.org/10.1002/hed.28126","url":null,"abstract":"<p><strong>Purpose: </strong>Hypercalcemia is the most common metabolic disorder in cancer, affecting 10%-20% of patients with advanced malignancies, including squamous cell carcinoma of the head and neck (HNSCC), though its prognostic significance remains poorly studied. This study aimed to evaluate the prognostic impact of hypercalcemia at diagnosis in patients with locally advanced or metastatic HNSCC and to explore underlying mechanisms and treatment options.</p><p><strong>Methods: </strong>We conducted a bicentric, retrospective analysis of patients diagnosed between 2015 and 2021, including those with locally advanced or metastatic HNSCC undergoing chemotherapy. Hypercalcemia at diagnosis was defined as an albumin-corrected serum calcium level > 2.6 mmol/L, equivalent to 10.4 mg/dL. The primary outcome was overall survival (OS), compared between hypercalcemic and non-hypercalcemic patients using multivariate analysis. Progression-free survival (PFS), along with clinical, biological, and therapeutic characteristics were also evaluated.</p><p><strong>Results: </strong>The study included 286 HNSCC patients, 225 (78.7%) of whom were male. Hypercalcemia incidence was 17.8%. The median OS for the cohort was 7.9 months (95% CI = 6.8-10.6). Hypercalcemic patients had a median OS of 5.9 months (95% CI = 3.8-7.9), compared to 9.1 months (95% CI = 7.3-11.7) in non-hypercalcemic patients (p = 0.002). In multivariate analysis, hypercalcemia was associated with worse OS (HR = 1.73, 95% CI = 1.17-2.56, p = 0.006). Median PFS was 4.3 months (95% CI = 3.6-5.5) for all patients. Hypercalcemic patients had a significantly shorter PFS of 2.4 months (95% CI = 1.9-4.8) compared to 4.7 months (95% CI = 3.8-5.9) in non-hypercalcemic patients (p = 0.0025). Multivariate analysis identified hypercalcemia and oral cavity tumors as negative prognostic factors, with HRs of 1.76 and 1.86, respectively. Bone metastasis rates were similar (17.6% vs. 16.2%), but local osteolysis was significantly higher in hypercalcemic patients (54.1% vs. 27.2%, p = 0.003). Bisphosphonates were administered to 38% of hypercalcemic patients.</p><p><strong>Conclusion: </strong>In this study, hypercalcemia was an independent negative prognostic factor of survival and rapid progression in patients with locally advanced or metastatic HNSCC.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143607022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of COVID-19 Vaccination on Treatment-Related Adverse Events and Oncologic Outcomes of Nonmetastatic Nasopharyngeal Carcinoma.","authors":"Minglong Liu, Bin Zhang, Yufei Pan, Xiaoping Lin, Guanhong Luo, Yuan Xie, Xiaolan Ruan, Yu Pan, Yi Liang, Defeng Wang, Yuejia Wei, Hengwei Chen, Guorong Tang, Wei Jiang","doi":"10.1002/hed.28130","DOIUrl":"https://doi.org/10.1002/hed.28130","url":null,"abstract":"<p><strong>Background: </strong>The influence of COVID-19 vaccination before chemoradiotherapy on nonmetastatic nasopharyngeal carcinoma (NPC) is not known.</p><p><strong>Methods: </strong>Propensity score matching was used to minimize potential selection bias between groups. Primary endpoints were treatment-related adverse events (TRAEs). The Kaplan-Meier method and Cox proportional hazards models were performed to conduct survival analysis. The Benjamini-Hochberg false discovery rate control procedure was used to adjust for multiple comparisons.</p><p><strong>Results: </strong>Eight hundred ninety-three patients with newly diagnosed nonmetastatic NPC were enrolled. On propensity score matching analysis, the vaccinated group exhibited a higher prevalence of neutropenia (p = 0.045) and fatigue (p = 0.010) during induction chemotherapy and a higher prevalence of fatigue (p = 0.015) during radiotherapy after adjustment for multiple comparisons. No significant differences were observed in 2-year OS, PFS, DMFS, and LRRFS in matched groups. Additionally, vaccinated patients exhibited a high and comparable absolute lymphocyte count.</p><p><strong>Conclusions: </strong>COVID-19 vaccination before chemoradiotherapy increases the prevalence of acute TRAEs, while no significant influence is observed on the oncologic outcomes of patients with nonmetastatic NPC.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143588366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective Registry Trial of Adjuvant High-Dose Rate Brachytherapy in Unirradiated Head and Neck Cancer: 20-Year Data.","authors":"Alejandro García-Consuegra, Marta Gimeno-Morales, Mauricio Cambeiro, José María López-Picazo, Juan Alcalde, Luis I Ramos, Luca Tagliaferri, José Luis Guinot, Francesco Bussu, Marta Moreno-Jiménez, Rafael Martinez-Monge","doi":"10.1002/hed.28131","DOIUrl":"https://doi.org/10.1002/hed.28131","url":null,"abstract":"<p><strong>Background and purpose: </strong>Full-dose postoperative external beam radiation therapy (EBRT)/chemoradiation is the standard of care in patients with resected, unirradiated head and neck cancer (HNC). This study aims to determine the long-term results of adjuvant high-dose rate (HDR) brachytherapy ± intermediate-dose postoperative external beam radiation therapy (EBRT)/chemoradiation in this HNC patient population.</p><p><strong>Materials and methods: </strong>From 2000 to 2018, a total of 152 patients diagnosed with HNC were treated with surgery and adjuvant HDR brachytherapy alone (n = 32) or combined with EBRT ± chemotherapy (n = 120). Patients treated with brachytherapy alone received 32 or 40 Gy in 8 or 10 b.i.d. fractions. Combined modality patients received 16 or 24 Gy of HDR brachytherapy in 4-6 b.i.d. fractions followed by EBRT 45 Gy in 25 fractions ± chemotherapy.</p><p><strong>Results: </strong>Median follow-up was 8.1 years (range, 0.1-21.6). Forty patients (26.3%) developed RTOG grade ≥ 3 adverse events, mainly soft tissue necrosis (11.2%) and osteoradionecrosis (6.6%). The 5-year local and locoregional control rates were 85.5% and 74.9%, respectively. Five-year disease-free survival and overall survival rates were 54.9% and 62.2%, respectively.</p><p><strong>Conclusion: </strong>Adjuvant HDR brachytherapy alone or combined with EBRT is an adequate treatment option for HNC patients who are candidates to receive postoperative radiation/chemoradiation. The results obtained in terms of toxicity and locoregional control are comparable to standard chemoradiation. In addition, this study identifies a subset of patients that may benefit from adjuvant HDR in terms of reduced toxicity, provided that the high-risk CTV does not exceed 15 cm³ and is treated to EQD2-DVH TV₁₀₀ doses of less than 87 Gy, together with a mandible_2cm3 of less than 61 Gy.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143588368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detection of PTEN Mutations in Fine Needle Aspiration Biopsies of Indeterminate Thyroid Nodules: Impact on Diagnosis and Prognosis.","authors":"Lauren E Schlegel, Madelaine Brill-Edwards, Zi-Xuan Wang, Christopher McNair, Stacey Gargano, Elizabeth Cottrill","doi":"10.1002/hed.28127","DOIUrl":"https://doi.org/10.1002/hed.28127","url":null,"abstract":"<p><strong>Background: </strong>Data connecting PTEN mutations with thyroid cancer risk for indeterminate nodules remain limited due to the rare nature of these mutations. The aim of this study was to determine the relationship between PTEN mutations identified in cytologically indeterminate nodules and final pathology and clinical outcomes.</p><p><strong>Methods: </strong>This 8-year retrospective study includes adults with indeterminate thyroid nodules positive for a PTEN mutation and available correlative surgical histopathology.</p><p><strong>Results: </strong>Twenty-three patients with 24 total nodules met the inclusion criteria. The cytology specimens were characterized as Bethesda III (n = 19) and Bethesda IV (n = 5). Specific PTEN mutations detected are described in detail. Final histopathology included the following: benign (n = 18, 75.0%), papillary thyroid carcinoma (n = 3, 12.5%), follicular thyroid carcinoma (n = 2, 8.3%), and poorly differentiated thyroid carcinoma (n = 1, 4.2%).</p><p><strong>Conclusions: </strong>Together, our data suggest that PTEN mutations in indeterminate thyroid nodules result in a 25.0% risk of malignancy (Bethesda III: 16.7% and Bethesda IV: 60%).</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143588364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pectoral-Sparing Deltoid Artery Use in the Vessel-Depleted Neck: A Pictorial Essay.","authors":"Arvind K Badhey, Priscilla Pichardo, Tazheh A Kavoosi, Brian Cervenka, Dustin Silverman, Alice Tang, Yash Patil, Chad Zender","doi":"10.1002/hed.28115","DOIUrl":"https://doi.org/10.1002/hed.28115","url":null,"abstract":"<p><strong>Background: </strong>This study demonstrates the role of the deltoid branch artery as a donor vessel for microvascular reconstruction in various free flaps in the vessel-depleted neck.</p><p><strong>Methods: </strong>This is a cohort study that reports our experience with 12 patients treated between January 5, 2020 and January 12, 2020 with free flap reconstruction utilizing the deltoid artery as a donor.</p><p><strong>Results: </strong>All patients had vessel-depleted necks secondary to previous surgery (75%), radiotherapy (100%), and/or chemotherapy (66%). Donor sites included radial forearm (n = 4), anterolateral thigh (n = 5), and latissimus dorsi (n = 3). All patients had complete flap survival, and none experienced major increases in morbidity.</p><p><strong>Conclusion: </strong>Our cohort demonstrated success using the deltoid artery for microvascular anastomosis in patients with vessel-depleted necks. It remains viable despite previous therapies. These data support the deltoid branch with a pectoral-sparing approach as a promising first-line arterial donor for various free flap reconstructions in patients with vessel-depleted necks.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Efficacy of Intra-Arterial Chemotherapy Combined With Immune Checkpoint Inhibitors in the Treatment of Advanced Head and Neck Squamous Cell Carcinoma.","authors":"Chao Yang, Jin-Long Zhang, Zheng Li, Xi-Hong Liang, Hong-Wei Zhao","doi":"10.1002/hed.28121","DOIUrl":"https://doi.org/10.1002/hed.28121","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the efficacy and safety of local intra-arterial chemotherapy combined with immune checkpoint inhibitors in the treatment of unresectable head and neck squamous cell carcinoma (HNSCC).</p><p><strong>Methods: </strong>A retrospective analysis was conducted on the clinical data of eight patients diagnosed with unresectable HNSCC at our hospital from January to December 2023. All patients were diagnosed by pathological diagnosis and treated with intra-arterial chemotherapy combined with immune checkpoint inhibitors. The overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and adverse reactions were observed.</p><p><strong>Results: </strong>The study cohort consisted of seven men and one woman, with a median age of 58.4 ± 13.1 years. Five patients were at stage IVA, one at stage IVB, and two at stage IVC. One patient was lost to follow-up, and among the 7 patients with complete data, the ORR was 85.7%. The median PFS and OS in the overall population were not achieved, and the patient tolerated the treatment well with no significant adverse effects.</p><p><strong>Conclusion: </strong>Local intra-arterial chemotherapy combined with immune checkpoint inhibitors is an important future exploration direction for the treatment of unresectable HNSCC.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined Tumor Infiltrating Lymphocytes and PD-L1 Status in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.","authors":"Catherine T Haring, Joshua D Smith, Sarah M Dermody, Jonathan B McHugh, William R Perry, Collin Brummel, Matthew E Spector, J Chad Brenner, Paul L Swiecicki","doi":"10.1002/hed.28128","DOIUrl":"https://doi.org/10.1002/hed.28128","url":null,"abstract":"<p><strong>Objectives: </strong>To determine if the assessment of CD8+ tumor-infiltrating lymphocytes (TILs) adds prognostic information to the PD-L1 combined positive score (CPS) in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).</p><p><strong>Methods: </strong>A retrospective case series was performed of 77 patients with R/M HNSCC between 2003 and 2019. From pre-treatment biopsies, CD8+ TILs and PD-L1 CPS were quantified on a tissue microarray. Associations of biomarkers with overall survival and immune checkpoint inhibition (ICI) response were assessed.</p><p><strong>Results: </strong>Neither CD8+ TIL counts nor PD-L1 CPS alone were associated with overall survival; however, combined high TILs and CPS ≥ 1 were associated with improved survival compared to low TILS and CPS < 1 (18.5 vs. 10.0 months, p = 0.058). For patients treated with ICI (n = 28), PD-L1 CPS predicted ICI response more strongly than CD8+ TILs.</p><p><strong>Conclusions: </strong>In R/M HNSCC, the combination of PD-L1 CPS and CD8+ TILs is a stronger prognostic biomarker for overall survival compared with either biomarker alone.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sinonasal NUT Carcinoma: A Systematic Review With Pooled Analysis and Report of a Case of Extraordinary Survival.","authors":"David Ahmadian, Shireen Samargandy, Fiona Anushi Liyanage, Phil Tseng, David Chen, Shethal Bearelly, Christopher Le","doi":"10.1002/hed.28129","DOIUrl":"https://doi.org/10.1002/hed.28129","url":null,"abstract":"<p><strong>Introduction: </strong>NUT carcinoma (NC) is a rare and aggressive malignancy often occurring in the midline structures of the head and neck. In this study, we present a systematic review and pooled analysis on patients specifically with sinonasal NC (SNC), as well as report a case of a patient with extraordinary survival following presentation with an NC of the maxillary sinus.</p><p><strong>Methods: </strong>Among 3042 articles retrieved, 27 were included in the final analysis. Clinical outcomes were described for a patient presenting with SNC at a tertiary academic medical center. Predictors of survival were evaluated with Kaplan-Meier (KM) and Cox regression analyses.</p><p><strong>Results: </strong>There were 45 patients with a relatively even gender distribution. The most common presenting symptoms were nasal obstruction (54%) and headache/facial pain (49%). Common primary sites of malignancy were the nasal cavity (50%), maxillary sinus (22%), and ethmoid sinus (16%). In terms of treatment, 31% underwent oncologic resection, 64% received radiation therapy, and 71% received chemotherapy. The overall cohort survival rate was 40% with an average survival of 12.4 months. The presence of nerve palsies (OR = 16.6, p < 0.001) was a substantial negative predictor for survival. Oncological resection with negative margins was associated with improved survival on KM analysis (p < 0.05). We also report a case of a 47-year-old female who presented with a left maxillary SNC with extra-sinus extension. She underwent a combined endoscopic/open oncologic resection with negative margins followed by chemoradiation. The patient remains alive 52 months after presentation.</p><p><strong>Conclusion: </strong>SNC remains an understudied clinical entity. Oncologic resection with negative margins is associated with improved survival. The presence of nerve palsies worsens overall survival. Further, large-scale studies are needed to determine optimal treatment protocols.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143558817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bitter Taste Receptor Agonists Induce Apoptosis in Papillary Thyroid Cancer.","authors":"Kimberly Wei, Brianna L Hill, Joel C Thompson, Zoey A Miller, Arielle Mueller, Robert J Lee, Ryan M Carey","doi":"10.1002/hed.28120","DOIUrl":"10.1002/hed.28120","url":null,"abstract":"<p><strong>Background: </strong>Papillary thyroid carcinoma (PTC) is the most common thyroid malignancy, with a 20% recurrence rate. Bitter taste receptors (T2Rs) and their genes (TAS2Rs) may regulate survival in solid tumors. This study examined T2R expression and function in PTC cells.</p><p><strong>Methods: </strong>Three PTC cell lines (MDA-T32, MDA-T68, and MDA-T85) were analyzed for expression using RT-qPCR and immunofluorescence. Live cell imaging measured calcium responses to six bitter agonists. Viability and apoptosis effects were assessed using crystal violet and caspase 3/7 activation assays. Genome analysis of survival was conducted.</p><p><strong>Results: </strong>TAS2R14 was consistently highly expressed in all cell lines. Five bitter agonists produced significant cytoplasmic and mitochondrial calcium responses across all cell lines. All bitter agonists significantly decreased viability and induced apoptosis. Higher TAS2R14 expression correlated with better progression-free survival in patients (p < 0.05).</p><p><strong>Conclusions: </strong>T2R activation by bitter agonists induces apoptosis, and higher TAS2R expression is associated with survival, suggesting potential therapeutic relevance in thyroid cancer management.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143558812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lenvatinib in Relapsed/Metastatic Adenoid Cystic Carcinoma: Real-World Data From 17 Italian Centers.","authors":"Francesca Caspani, Stefano Cavalieri, Ester Orlandi, Cristiana Bergamini, Carlo Resteghini, Elena Colombo, Arianna Ottini, Imperia Nuzzolese, Salvatore Alfieri, Aurora Mirabile, Alessandra Cassano, Paolo Bossi, Toni Ibrahim, Maria Chiara Cau, Massimo Ghiani, Federica Bertolini, Rossana Ingargiola, Giulia Fontana, Lisa Licitra, Laura D Locati","doi":"10.1002/hed.28124","DOIUrl":"https://doi.org/10.1002/hed.28124","url":null,"abstract":"<p><strong>Background: </strong>Lenvatinib, a multi-target tyrosine kinase inhibitor (MTKI), has demonstrated activity in recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC) in phase II studies.</p><p><strong>Methods: </strong>This multicenter, retrospective study included patients with R/M ACC treated with lenvatinib. The primary endpoint was the overall response rate (ORR).</p><p><strong>Results: </strong>Fifty-one patients were included across 17 Italian sites. Forty-six patients (90%) were evaluated for response: the ORR was 21.7%, with 10 patients achieving a partial response; 24 patients had a stable disease resulting in a disease control rate of 73.9%. At least one treatment-related adverse event (TRAE) was recorded in all patients. The most frequent TRAEs of grade > 3 were hypertension (25.5%), stomatitis (17.6%), and fatigue (15.7%); one grade 5 TRAE (bleeding) was reported. Median OS was 16.1 months (95% CI 12.2-NR) with six-month PFS at 75.7%.</p><p><strong>Conclusion: </strong>Lenvatinib confirmed its activity in the real-world population. A higher than expected rate of grade > 3 stomatitis was reported.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143544572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}